Amphastar signs related-party contract research deal with Hanxin, up to $2.8 million
Amphastar Pharmaceuticals entered a three-year contract research agreement on September 15, 2025 with Nanjing Hanxin Pharmaceutical Technology, a company majority-owned by the CEO, COO and Chairman's family. Hanxin will develop cell banks the company will own and use for its product candidate AMP-107, with total cost not expected to exceed about $2.8 million. The deal is with a related party, and the independent Audit Committee approved it.
Key points
- Agreement effective September 15, 2025, with a term of three years
- Total cost to Amphastar not to exceed approximately $2.8 million, paid in Chinese yuan and adjusted for exchange rates
- Approximately $0.3 million payable to Hanxin on the Effective Date
- Dr. Jack Zhang and Dr. Mary Luo and family members own a majority of Hanxin; independent Audit Committee approved the deal
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 18, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.